Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) updated its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 1.800-1.900 for the period, compared to the consensus estimate of 1.600. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion.

Embecta Stock Performance

Shares of EMBC stock traded up $0.92 on Friday, hitting $4.42. The company had a trading volume of 5,584,758 shares, compared to its average volume of 1,573,620. Embecta has a twelve month low of $2.77 and a twelve month high of $15.55. The firm has a market cap of $262.24 million, a P/E ratio of 2.33 and a beta of 0.81. The stock’s 50-day moving average is $3.32 and its two-hundred day moving average is $6.67.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The company had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. During the same period in the previous year, the firm earned $1.12 earnings per share. The firm’s quarterly revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities research analysts predict that Embecta will post 1.62 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EMBC. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Bank of America reduced their price objective on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Weiss Ratings lowered shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. Finally, Mizuho lowered their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $11.00.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Embecta reported fiscal Q3 2026 earnings of $0.56 per share, well above the $0.27 analyst consensus, while revenue of $271.7 million exceeded expectations of $254.5 million. The results provide a near-term catalyst despite revenue declining 8.1% year over year. Embecta quarterly earnings report
• Positive Sentiment: The company raised fiscal 2026 adjusted EPS guidance to $1.80-$1.90, above the prior analyst consensus of approximately $1.60. The improved outlook is likely the primary reason investors are bidding up EMBC. Embecta fiscal 2026 results and guidance
• Positive Sentiment: Embecta declared a quarterly cash dividend of $0.01 per share, reinforcing shareholder returns, although the payout is modest. Embecta dividend announcement
• Neutral Sentiment: Management continues repositioning Embecta from an insulin-delivery specialist into a broader medical-supplies company. The strategy could diversify long-term growth but also introduces execution and competitive risks. Embecta investor notice
• Negative Sentiment: Multiple law firms publicized a securities class action against Embecta and certain executives. The allegations concern statements about the commercial stability of its insulin pen-needle business, covering investors who purchased securities between November 25, 2025, and May 4, 2026. Investors have until August 17, 2026 to seek lead-plaintiff status. The litigation creates potential legal costs, damages and reputational risk. Embecta securities class action notice

Institutional Investors Weigh In On Embecta

Large investors have recently modified their holdings of the stock. Larson Financial Group LLC lifted its position in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares during the period. Wexford Capital LP bought a new position in shares of Embecta in the third quarter worth $94,000. Humankind Investments LLC bought a new position in Embecta in the 2nd quarter worth about $111,000. Finally, iSAM Funds UK Ltd purchased a new position in Embecta during the 3rd quarter valued at about $115,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.